TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to provide written informed consent~* Peripheral capillary oxygen saturation (SpO2) ≥ 95% on room air at screening~* Age ≥18 years~Exclusion Criteria:~* Hospitalized or impending hospitalization at the time of screening~* Symptoms of cough, fever or shortness of breath within 72 hours~* Prior or current treatment with other experimental or approved agents targeting SARS-CoV-2 or SARS-CoV-1~* Positive pregnancy test~* Active autoimmune disease or sarcoidosis (with the exception of controlled thyroid disease)~* Active decompensated liver disease (ascites, encephalopathy)~* Active congestive heart failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Peginterferon lambda alfa-1a (Type: EXPERIMENTAL): peginterferon lambda-1a (Lambda) 180 micrograms by subcutaneous injection for participants who are not infected with SARS-CoV-2
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (saline) by subcutaneous injection for participants who are not infected with SARS-CoV-2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Performance Study of the Siello S Pacing Lead

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Candidate for de novo implantation of a BIOTRONIK pacemaker system, including one or two Siello S leads. Candidate meets recommendation for pacemaker system implant put forth by guidelines of relevant professional societies.~* Able to understand the nature of the study and provide informed consent.~* Available for follow-up visits on a regular basis at the investigational site for the expected 5 years of follow-up.~* Age greater than or equal to 18 years.~Exclusion Criteria:~* Enrolled in any other investigational clinical study.~* Currently implanted with a pacemaker or ICD device.~* Planned cardiac surgical procedures or interventional measures within the next 6 months.~* Expected to receive a heart transplant within 1 year.~* Life expectancy less than 1 year.~* Presence of another life-threatening, underlying illness separate from their cardiac disorder.~* Pregnant at the time of enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pacemaker Therapy (Type: None): Patients with a market-released BIOTRONIK pacemaker system including one or two Siello S leads.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients 18 years or older with body weight \>40kg~* Written informed consent~* Presented within 48 hours of onset of influenza-like illness~* Presumptive diagnosis of H1N1 satisfying the following clinical and laboratory criteria:~  * Clinical criteria~    * Fever \>38 oC (Infrared Forehead Thermometer will be used to measure the Temporal Artery Temperature under the skin) AND~   * At least one upper respiratory tract infection (cough, running nose, sore throat)~ * Laboratory criteria Positive rapid test result for influenza A (by Influenza Rapid Diagnostic test) within 48 hours of onset of flu-like symptoms~Exclusion Criteria:~* Age below 18 years~* Persons who lack the ability to care for themselves~* Patient with critical condition or already developed severe respiratory distress with hypoxaemia on presentation~* Pregnancy or lactation~* Coexisting liver disease~* Coexisting cardiovascular disease except stable hypertension without complication~* Coexisting chronic pulmonary disease~* Coexisting immuno-compromised medical conditions or on concurrent immunosuppressive therapies~* Renal failure~* Terminal malignancies or terminal end-organ failure with an estimated life-expectancy of less than 3 months~* Known intolerance to oseltamivir or zanamivir~* Known history of significant neurological disorders that can compromise respiratory function or the handling of respiratory secretions or that can increase the risk for aspiration or those~* Subjects who have received oseltamivir as prophylaxis for H1N1 infection~* Subjects who have received any investigational drug within 1 month prior to study entry~* Subjects with a mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oseltamivir (Type: EXPERIMENTAL): None
- Zanamivir (Type: EXPERIMENTAL): None
- Placebo of Oseltamivir (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
inclusion criteria~* Adult patient (age ≥ 18 years old);~* Hospitalized in intensive care ;~* Severe COVID-19 pneumonia (positive diagnosis by RT-PCR or SARS-CoV-2 antigen test on nasopharyngeal or deep respiratory specimen and/or evocative thoracic scan: frosted glass opacities, consolidation, cross-linking, thickening of interlobular septa, peripheral nodules) with ARDS criteria according to Berlin criteria (PaO2/FiO2 ≤ 300 and PEP ≥ 5).~* With respiratory assistance (intubated or NIV or ONHD) for less than 8 days;~* With an expected duration of respiratory assistance \> 48 hours;~* Carrier of an arterial catheter ;~* For which 4 PaO2/FiO2 values on arterial blood over the last 24 hours are available;~Exclusion Criteria:~* Known hypersensitivity to Dornase alfa or any of the excipients;~* Pregnant or breastfeeding status;~* Patient with legal protection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental group (Type: EXPERIMENTAL): Dornase alfa will be administered by nebulization, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days, using a vibrating mesh nebulizer. The remainder of the management will be performed in accordance with good practice, including mechanical ventilation (protective ventilation, PEEP \> 5 cmH2O, tracheal balloon pressure checking every 4 hours or automatic device, 30° head of the bed elevation, tidal volume 6-8mL/kg, plateau pressure \< 30cmH2O), neuromuscular blockers if necessary, prone position if PaO2/FiO2\<150, early enteral nutrition, glycemic control, a sedation protocol based on the RASS score.
- Control group (Type: ACTIVE_COMPARATOR): Patients will receive the usual care in accordance with good practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Weight Management for the Remission of Type 2 Diabetes Using a Proprietary Meal Replacement System- Diabetes Remission Study (DRS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and Women~* Ages 25-65~* Have been diagnosed with non-insulin dependent diabetes for less than five years~* Are taking at least one oral agents for diabetes~* English speaking~Exclusion Criteria:~* Individuals currently being treated for cancer~* Had a myocardial infarction in the previous 3 months~* Have uncontrolled persistent hypertension - diastolic \>90 systolic \>160~* Individuals with established eating disorder diagnoses~* Individuals who have recent weight loss attempt in the last 3 months with \> 5-pound loss~* Use of anti-obesity medications in the last three months~* Individuals who have had bariatric surgery~* Individuals taking medications that are known to cause weight gain including but not limited to insulin, steroids, haloperidol clozapine, risperidone, olanzapine, amitriptyline imipramine, paroxetine, and lithium~* Individuals who are pregnant or planning to become pregnant in the next 6 months

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): Replace meals with a plant-based meal replacement and self-prepared Meditteranean meals for a max 1200 calorie per day. Enroll in a 12 week intensive lifestyle intervention program.
- Standard of Care Group (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* idiopathic PD with bradykinesia and at least two of the following signs; resting tremor, rigidity, and asymmetry (in accordance with clinical diagnostic criteria of the UK PD Society Brain Bank);~* the presence of minor VH for at least 4 weeks, defined by a score of 1 or 2 on the hallucinations item of the Unified Parkinson's Disease rating Scale (UPDRS)1-MDS;~* age 40 years and over.~Exclusion Criteria:~* Parkinson's Disease Psychosis, defined as the need for antipsychotic drug treatment in the opinion of the treating neurologist;~* Parkinson's Disease Dementia, defined by a score \< 24 on the Mini Mental State Examination (MMSE);~* current delirium (caused by infection or metabolic disturbance);~* current treatment with amantadine (Symmetrel) or anti-cholinergics, such as trihexyfenidyl (Artane) or biperideen (Akineton);~* current or recent (\<6 months) treatment with Cholinesterase inhibitor, such as rivastigmine (Exelon) or galantamine (Reminyl);~* recent (\<1 month) change in dopaminergic therapy;~* history of psychosis or severe ophtalmologic disease (e.g. Charles Bonnet syndrome);~* permanent stay in a nursing home;~* no informed consent.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): placebo capsule for oral use 6,0 mg BID during 24 months of follow-up
- Rivastigmine (Type: EXPERIMENTAL): rivastigmine capsule for oral use 6,0 mg BID during 24 months of follow-up

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Plastic vs. Fully Covered Self Expanding Stents (FCSEMS) for Treatment of Anastomotic Bile Leaks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients undergoing ERCP for suspected anastomotic bile leak within 60 days following OLT with standard biliary reconstruction~* cognitively impaired population with a surrogate who has legal power of attorney~Exclusion Criteria:~* patients who have undergone OLT with hepaticojejunostomy~* patients who have undergone percutaneous transhepatic cholangiogram with percutaneous biliary intervention following OLT and prior to ERCP

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Plastic Biliary Stent (Type: ACTIVE_COMPARATOR): Subjects with anastomotic bile leaks following orthotopic liver transplant (OLT) will have a temporary plastic biliary stent placed across the site of the leak during retrograde cholangiopancreatography (ERCP).
- FCSEMS (Type: ACTIVE_COMPARATOR): Subjects with anastomotic bile leaks following orthotopic liver transplant (OLT) will have a temporary fully covered self-expanding metal stent (FCSEMS) placed across the site of the leak during retrograde cholangiopancreatography (ERCP).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Docosahexaenoic Acid (DHA)-Enriched Human Milk in Premature Newborns

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Childbirth between 34 and 35 GA~* Breast-feeding~* Caucasian~* Affiliation to social security~* Obtained consent from mother, and parents for the child~* Mother with balanced diet~* No allergy to eggs~* Single pregnancy~Exclusion Criteria:~* Allergy to egg~* Unbalanced diet~* Diabetes~* Known digestive disease~* Counter-indication with breast-feeding~* Cigarettes (more than 5 per day)~* Alcoholism (daily consumption of alcohol)~* Multiple pregnancy

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- TG-DHA (Type: ACTIVE_COMPARATOR): TG-DHA: lactating mothers and their newborn with mothers supplemented with Triglyceride enriched in docosahexaenoic acid
- Control (Type: NO_INTERVENTION): Control: lactating mothers and their newborn with no supplementation given to the mother
- GPL-DHA (Type: EXPERIMENTAL): GPL-DHA: lactating mothers and their newborn with mothers supplemented with Glycerophospholipid enriched in docosahexaenoic acid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Accommodation Measurements After Bilateral Implantation of an Aspheric Accommodating Lens and Monofocal Aspheric Lenses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have clear intraocular media other than cataract.~* Subjects must have a clinically documented diagnosis of age-related bilateral cataracts that are considered amenable to treatment with standard phacoemulsification cataract extraction.~* Subjects must be undergoing primary IOL implantation for the correction of aphakia following central continuous curvilinear anterior capsulorrhexis and phacoemulsification cataract extraction.~* Subjects must require a spherical lens power from 10.00 D to 30.00 D.~* Subjects must be willing and able to return for all scheduled follow-up examinations for each eye from days 1 through 180 following surgery.~* Subjects must have ≤ 1.25 D of preoperative corneal astigmatism.~Exclusion Criteria:~* Subjects with corneal pathology potentially affecting topography.~* Subjects whose fundus cannot be assessed preoperatively.~* Subjects with diagnoses of degenerative visual disorders (eg, macular degeneration, or other retinal disorders) that cause potential acuity losses to a level worse than 20/30 as verified by OCT.~* Subjects with conditions with increased risk of zonular rupture, such as pseudoexfoliation syndrome.~* Subjects who have any active inflammation or edema (swelling) of the cornea, including but not limited to the following: keratitis, keratoconjunctivitis, and keratouveitis.~* Subjects with uncontrolled glaucoma.~* Subjects with previous retinal detachment.~* Subjects with visually significant diabetic retinopathy (proliferative or non-proliferative) which reduces potential acuity to 20/30 or worse.~* Subjects with rubella, bilateral congenital, traumatic, complicated or polar cataract.~* Subjects with marked microphthalmos or aniridia.~* Subjects who have had previous corneal surgery.~* Subjects with irregular corneal astigmatism.~* Subjects with amblyopia which reduces potential acuity to worse than 20/30.~* Subjects with optic atrophy.~* Subjects with iris neovascularization.~* Subjects with clinically significant retinal pigment epithelium/macular changes which reduces potential acuity to 20/30 or worse.~* Subjects with chronic use of systemic steroids or immunosuppressive medications.~* Subjects lacking intact binocular vision.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Crystalens AO (Type: EXPERIMENTAL): A silicone multi-piece accommodating intraocular lens
- SoftPort LI61AO (Type: ACTIVE_COMPARATOR): A silicone multi-piece foldable aspheric intraocular lens

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Gastric Tube on the Quality of Life and Nutritional Status After Ivor-Lewis Esophagectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* esophageal cancer (squamous and adenocarcinoma subtypes)~* eligble for Ivor-Lowis esophagectomy~* expected survival time longer than 12 months~Exclusion Criteria:~* palliative resection(non-R0)~* anastomosis leak~* jejunum or colon transversum interponate

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- gastirc tube group (Type: EXPERIMENTAL): conduit will be perfomed by narrowed gastric tube
- control group (Type: NO_INTERVENTION): conduit will be traditional subtotal stomach without any surgical modification

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Complete initial resection by a BCa-focused urologic oncologist; mandatory bladder detrusor muscle in the initial TURBT specimen and complete visible resection documented by the surgeon/OR staff by intra-operative photography.~* Urothelial carcinoma as the predominant histology as determined by genitourinary specific pathologist (e.g. small (\<50%) components of small cell, squamous cell or adenocarcinoma are allowable).~* Able and willing to consent.~* ≥18 years old: BCa is primarily a disease of the elderly, thus we have elected to include healthy octogenarian/nonagenarian patients. Additionally, since a TURBT can be performed under general or spinal anesthesia, we feel that including these patients is acceptable.~Exclusion Criteria:~* Lymph node or distant metastases at initial presentation - determined on standard BCa staging evaluation with a CT-urogram of the abdomen/pelvis and/or a preoperative chest x-ray demonstrating pulmonary metastases.~* Extensive NMIBC disease warranting immediate cystectomy.~* Variant histology (not urothelial carcinoma) - ie. micropapillary, plasmacytoid, nested or sarcomatoid variants.~* No muscularis propria (inadequate bladder staging) present in the initial TURBT specimen.~* Initial TURBT demonstrating T1HG disease performed outside of study centre - as per study protocol, quality control of surgical performance for this trial requires the TURBT to be performed by an experienced BCa-dedicated surgeon.~* Patients with severe comorbidities, including but not limited to: (i) previous stroke with persistent cognitive, motor, etc deficits; (ii) recent (\<6 months) myocardial infarction or current unstable angina; (iii) liver cirrhosis; (iv) severe chronic obstructive pulmonary disease (COPD)/respiratory disease. Patients must be suitable candidates for either spinal or general anesthesia.~* Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- re-TURBT (Type: EXPERIMENTAL): Patients in this arm will receive a 2nd TURBT within 4-6 weeks of initial TURBT
- 6 BCG instillations (Type: ACTIVE_COMPARATOR): Patients in this arm will not receive a 2nd TURBT, but will receive 6 instillations of BCG.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Enzyme Replacement Therapy in Fabry Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 16 years and ≤ 65 years~* clinical diagnosis of Fabry disease, confirmed by α-galactosidase A assay and detection of mutation in α-GalA gene~* serum creatinine ≥ 1.4 mg/dl (females) and ≥ 1.6 mg/dl (males) and/or proteinuria ≥ 0.4 g/24h~* written informed consent~Exclusion Criteria:~* any clinically relevant condition that may affect study participation and/or study results~* inability to fully understand the purpose and the risks of the study

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Patients with Fabry disease (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues